Skip to main content
Erschienen in: Calcified Tissue International 1/2004

01.01.2004 | Laboratory Investigations

Effects of Weekly Administrations of Alendronate+Clodronate on Young Mouse Tibia: Localized Action at the Proximal Growth Plate

verfasst von: Y. Monma, H. Funayama, H. Mayanagi, Y. Endo

Erschienen in: Calcified Tissue International | Ausgabe 1/2004

Einloggen, um Zugang zu erhalten

Abstract

Alendronate (A), a typical aminobisphosphonate (aminoBP), has a strong bone-resorption-inhibitory activity (BRIA). However, like other aminoBPs it has inflammatory side effects. In contrast, the BRIA of clodronate (C), a non-aminoBP, is much weaker, and in animal experiments it suppresses aminoBP-induced inflammatory reactions. In the present study, we examined the effects of weekly administrations of A (1.6 µmol/kg) + C (160 µmol/kg) on the tibias in young mice and compared them to those induced by A or C alone. Radiophotography showed that A increased bone density at a selective site in the tibia. Indeed, one week after the final injection of A (given alone), clear sclerotic lines (tentatively called BP-lines) were visible at sites corresponding to the location of the growth plate at the time of the each injection. C also produced BP-lines, although they were weaker than those produced by A. Combined administration of A and C produced similar BP-lines as seen in mice given A alone. These results together with other physicochemical effects of A on the tibia suggest that (1) each injection of A and C inhibits bone resorption selectively and transiently at the tibial growth plate in young mice, although minor effects on other sites cannot be excluded, and (2) the combination of A and C keeps still a strong BRIA. Our findings may suggest a strategy for the prevention or reduction of some inflammatory side effects of A or other aminoBPs.
Literatur
1.
Zurück zum Zitat Rodan, GA, Fleisch, HA 1996Bisphosphonates: mechanism of action.J Clin Invest9726922696PubMed Rodan, GA, Fleisch, HA 1996Bisphosphonates: mechanism of action.J Clin Invest9726922696PubMed
2.
Zurück zum Zitat Bonjour, JP, Rizzoli, R, Ammann, P, Chevalley, T 1994Bisphosphonates in clinical medicine.Heershe, NMKanis, JK eds. Bone and Mineral Research, vol 8.Elsevier Science BVAmsterdam205264 Bonjour, JP, Rizzoli, R, Ammann, P, Chevalley, T 1994Bisphosphonates in clinical medicine.Heershe, NMKanis, JK eds. Bone and Mineral Research, vol 8.Elsevier Science BVAmsterdam205264
3.
Zurück zum Zitat Geddes, AD, D’Souza, SM, Ebentino, FH, Kenneth, JI 1994Bisphosphonates: structure-activity relationships and therapeutic implications.Heershe, NMKanis, JK eds. Bone and Mineral Research, vol 8.Elsevier Science BVAmsterdam265306 Geddes, AD, D’Souza, SM, Ebentino, FH, Kenneth, JI 1994Bisphosphonates: structure-activity relationships and therapeutic implications.Heershe, NMKanis, JK eds. Bone and Mineral Research, vol 8.Elsevier Science BVAmsterdam265306
4.
Zurück zum Zitat Glorieux, FH, Bishop, NJ, Plotkin, H, Chabot, G, Lanoue, G, Travers, R 1998Cyclic administration of pamidronate in children with severe osteogenesis imperfecta.N Engl J Med339947952 Glorieux, FH, Bishop, NJ, Plotkin, H, Chabot, G, Lanoue, G, Travers, R 1998Cyclic administration of pamidronate in children with severe osteogenesis imperfecta.N Engl J Med339947952
5.
Zurück zum Zitat Adami, S, Bhalla, AK, Dorizzi, R, Montesani, F, Rosini, S, Salvagno, G, Lo Cascio, V 1987The acute phase response after bisphosphonate administration.Calcif Tissue Int41326331PubMed Adami, S, Bhalla, AK, Dorizzi, R, Montesani, F, Rosini, S, Salvagno, G, Lo Cascio, V 1987The acute phase response after bisphosphonate administration.Calcif Tissue Int41326331PubMed
6.
Zurück zum Zitat Sauty, A, Pecherstorfer, M, Zimmer-Roth, I, Fioroni, P, Juillerat, L, Markert, M, Ludwig, H, Leuenberger, P, Burckhardt, P, Thiébaud, D 1996Interleukin-6 and tumor necrosis factor α levels after bisphosphonates treatment in vitro and in patients with malignancy.Bone18133139CrossRefPubMed Sauty, A, Pecherstorfer, M, Zimmer-Roth, I, Fioroni, P, Juillerat, L, Markert, M, Ludwig, H, Leuenberger, P, Burckhardt, P, Thiébaud, D 1996Interleukin-6 and tumor necrosis factor α levels after bisphosphonates treatment in vitro and in patients with malignancy.Bone18133139CrossRefPubMed
7.
Zurück zum Zitat Thiébaud, D, Sauty, A, Burckhardt, P, Leuenberger, P, Sitzler, L, Green, JR, Kandra, A, Zieschang, J, Ibarra de Palacios, P 1997An in vitro and in vivo study of cytokines in the acute-phase response associated with bisphosphonates.Calcif Tissue Int61386392CrossRefPubMed Thiébaud, D, Sauty, A, Burckhardt, P, Leuenberger, P, Sitzler, L, Green, JR, Kandra, A, Zieschang, J, Ibarra de Palacios, P 1997An in vitro and in vivo study of cytokines in the acute-phase response associated with bisphosphonates.Calcif Tissue Int61386392CrossRefPubMed
9.
Zurück zum Zitat Macarol, V, Frauenfelder, FT 1994Pamidronate disodium and possible ocular adverse drug reactions.Am J Ophthamol118220224 Macarol, V, Frauenfelder, FT 1994Pamidronate disodium and possible ocular adverse drug reactions.Am J Ophthamol118220224
10.
Zurück zum Zitat Fleisch, HA 1997Bisphosphonates: preclinical aspects and use in osteoporosis.Anal Med295662 Fleisch, HA 1997Bisphosphonates: preclinical aspects and use in osteoporosis.Anal Med295662
11.
Zurück zum Zitat Mönkkönen, J, Koponen, HM, Ylitalo, P 1989Comparison of the distribution of three bisphosphonates in mice.Pharmacol Toxicol65294298 Mönkkönen, J, Koponen, HM, Ylitalo, P 1989Comparison of the distribution of three bisphosphonates in mice.Pharmacol Toxicol65294298
12.
Zurück zum Zitat Endo, Y, Nakamura, N, Kikuchi, T, Shinoda, H, Takeda, K, Nitta, Y, Kumagai, K 1993Aminoalkylbisphosphonates, potent inhibitors of bone resorption, induce a prolonged stimulation of histamine synthesis and increase macrophages, granulocytes, and osteoclasts in vivo. Calcif Tissue Int52248254PubMed Endo, Y, Nakamura, N, Kikuchi, T, Shinoda, H, Takeda, K, Nitta, Y, Kumagai, K 1993Aminoalkylbisphosphonates, potent inhibitors of bone resorption, induce a prolonged stimulation of histamine synthesis and increase macrophages, granulocytes, and osteoclasts in vivo. Calcif Tissue Int52248254PubMed
13.
Zurück zum Zitat Nakamura, M, Ando, T, Masataka, A, Kumagai, K, Endo, Y 1996Contrast between effects of aminobisphosphonates and non-aminobisphosphonates on collagen-induced arthritis in mice.Br J Pharmacol119205212PubMed Nakamura, M, Ando, T, Masataka, A, Kumagai, K, Endo, Y 1996Contrast between effects of aminobisphosphonates and non-aminobisphosphonates on collagen-induced arthritis in mice.Br J Pharmacol119205212PubMed
14.
Zurück zum Zitat Sugawara, S, Shibazaki, M, Takada, H, Kosugi, K, Endo, Y 1998Contrasting effects of an aminobisphosphonate, a potent inhibitor of bone resorption, on lipopolysaccharide-induced production of interleukin-1 and tumour necrosis factor α in mice.Br J Pharmacol125735740PubMed Sugawara, S, Shibazaki, M, Takada, H, Kosugi, K, Endo, Y 1998Contrasting effects of an aminobisphosphonate, a potent inhibitor of bone resorption, on lipopolysaccharide-induced production of interleukin-1 and tumour necrosis factor α in mice.Br J Pharmacol125735740PubMed
15.
Zurück zum Zitat Funayama, H, Mayanagi, H, Takada, H, Endo, Y 2000Elevation of histidine decarboxylase activity in the mandible of mice by Prevotella intermedia lipopolysaccharide and its augmentation by an aminobisphosphonate.Arch Oral Biol45787795CrossRefPubMed Funayama, H, Mayanagi, H, Takada, H, Endo, Y 2000Elevation of histidine decarboxylase activity in the mandible of mice by Prevotella intermedia lipopolysaccharide and its augmentation by an aminobisphosphonate.Arch Oral Biol45787795CrossRefPubMed
16.
Zurück zum Zitat Yamaguchi, K, Motegi, K, Iwakura, Y, Endo, Y 2000Involvement of interleukin-1 in the inflammatory actions of aminobisphosphonates in mice.Br J Pharmacol13016461654PubMed Yamaguchi, K, Motegi, K, Iwakura, Y, Endo, Y 2000Involvement of interleukin-1 in the inflammatory actions of aminobisphosphonates in mice.Br J Pharmacol13016461654PubMed
17.
Zurück zum Zitat Endo, Y, Shibazaki, M, Nakamura, M, Kosugi, H 1999Inhibition of inflammatory actions of aminobisphosphonates by dichloromethylene bisphosphonate, a non-aminobisphosphonate.Br J Pharmacol126903910PubMed Endo, Y, Shibazaki, M, Nakamura, M, Kosugi, H 1999Inhibition of inflammatory actions of aminobisphosphonates by dichloromethylene bisphosphonate, a non-aminobisphosphonate.Br J Pharmacol126903910PubMed
18.
Zurück zum Zitat Kasting, GB, Francis, MD 1992Retention of etidronate in human, dog, and rat.J Bone Miner Res7513522 Kasting, GB, Francis, MD 1992Retention of etidronate in human, dog, and rat.J Bone Miner Res7513522
19.
Zurück zum Zitat Devogelaer, JP, Malghem, J, Maldague, B, Nagant de Deuxchaisnes, D 1987Radiological manifestation of bisphosphonate treatment with APD in a child suffering from osteogenesis imperfecta.Skeletal Radiol16360363PubMed Devogelaer, JP, Malghem, J, Maldague, B, Nagant de Deuxchaisnes, D 1987Radiological manifestation of bisphosphonate treatment with APD in a child suffering from osteogenesis imperfecta.Skeletal Radiol16360363PubMed
20.
Zurück zum Zitat Sato, M, Grasser, W, Endo, N, Akins, R, Simmons, H, Thompson, DD, Golub, E, Rodan, GA 1991Bisphosphonate action: alendronate localization in rat bone and effects on osteoclast ultrastructure.J din Invest8820952105 Sato, M, Grasser, W, Endo, N, Akins, R, Simmons, H, Thompson, DD, Golub, E, Rodan, GA 1991Bisphosphonate action: alendronate localization in rat bone and effects on osteoclast ultrastructure.J din Invest8820952105
21.
Zurück zum Zitat Amin, D, Cornell, SA, Gustafson, SK, Needle, SJ, Ullrich, JW, Bilder, GE, Perrone, MH 1992Bisphosphonates used for the treatment of bone disorders inhibit squalene synthase and cholesterol biosynthesis.J Lipid Res3316571663PubMed Amin, D, Cornell, SA, Gustafson, SK, Needle, SJ, Ullrich, JW, Bilder, GE, Perrone, MH 1992Bisphosphonates used for the treatment of bone disorders inhibit squalene synthase and cholesterol biosynthesis.J Lipid Res3316571663PubMed
22.
Zurück zum Zitat Amin, D, Cornell, SA, Perrone, MH, Bilder, GE 19961-Hydroxy-3-(methylpentylamino)-propylidene-1,1-bisphosphonic acid as a potent inhibitor of squalene synthase.Drug Res46759762 Amin, D, Cornell, SA, Perrone, MH, Bilder, GE 19961-Hydroxy-3-(methylpentylamino)-propylidene-1,1-bisphosphonic acid as a potent inhibitor of squalene synthase.Drug Res46759762
23.
Zurück zum Zitat Fisher, JE, Rogers, MJ, Halasy, JM, et al. 1999Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclasts formation, bone resorption, and kinase activation in vitro.Proc Natl Acad Sci USA96133138CrossRefPubMed Fisher, JE, Rogers, MJ, Halasy, JM,  et al. 1999Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclasts formation, bone resorption, and kinase activation in vitro.Proc Natl Acad Sci USA96133138CrossRefPubMed
24.
Zurück zum Zitat Van Beek, E, Löwik, C, Van Der Pluijm, G, Papapoulos, S 1999The role of geranylgeranylation in bone resorption and its suppression by bisphosphonates in fetal bone explants in vitro: a clue to the mechanism of action of nitrogen-containing bisphosphonates.J Bone Miner Res14722729 Van Beek, E, Löwik, C, Van Der Pluijm, G, Papapoulos, S 1999The role of geranylgeranylation in bone resorption and its suppression by bisphosphonates in fetal bone explants in vitro: a clue to the mechanism of action of nitrogen-containing bisphosphonates.J Bone Miner Res14722729
25.
Zurück zum Zitat Van Beek, E, Pieterman, E, Cohen, L, Löwik, C, Papapoulos, S 1999Nitrogen-containing bisphosphonates inhibit isopentenyl pyrophosphate isomerase/farnesyl pyrophosphate synthase activity with relative potencies corresponding to their antiresorptive potencies in vitro and in vivo. Biochem Biophys Res Commun255491494PubMed Van Beek, E, Pieterman, E, Cohen, L, Löwik, C, Papapoulos, S 1999Nitrogen-containing bisphosphonates inhibit isopentenyl pyrophosphate isomerase/farnesyl pyrophosphate synthase activity with relative potencies corresponding to their antiresorptive potencies in vitro and in vivo. Biochem Biophys Res Commun255491494PubMed
26.
Zurück zum Zitat Van Beek, E, Pieterman, E, Cohen, L, Löwik, C, Papapoulos, S 1999Farnesyl pyrophosphate synthase is the molecular target of nitrogen-containing bisphosphonates.Biochem Biophys Res Commun264108111CrossRefPubMed Van Beek, E, Pieterman, E, Cohen, L, Löwik, C, Papapoulos, S 1999Farnesyl pyrophosphate synthase is the molecular target of nitrogen-containing bisphosphonates.Biochem Biophys Res Commun264108111CrossRefPubMed
27.
Zurück zum Zitat Martin, MB, Arnold, W, Heath, HT, Urbina, JA, Oldfield, E 1999Nitrogen-containing bisphosphonates as carbocation transition state analogs for isoprenoid biosynthesis.Biochem Biophys Res Commun263754758CrossRefPubMed Martin, MB, Arnold, W, Heath, HT, Urbina, JA, Oldfield, E 1999Nitrogen-containing bisphosphonates as carbocation transition state analogs for isoprenoid biosynthesis.Biochem Biophys Res Commun263754758CrossRefPubMed
28.
Zurück zum Zitat Keller, K, Fliesler, SJ 1999Mechanism of aminobisphosphonate action: characterization of alendronate inhibition of isoprenoid pathway.Biochem Biophys Res Commun266560563CrossRefPubMed Keller, K, Fliesler, SJ 1999Mechanism of aminobisphosphonate action: characterization of alendronate inhibition of isoprenoid pathway.Biochem Biophys Res Commun266560563CrossRefPubMed
29.
Zurück zum Zitat Frith, JC, Mönkkönen, J, Blackburn, GM, Russel, RG, Rogers, MJ 1997Clodronate and liposome-encapsulated clodronate are metabolized to a toxic ATP analog, adenosine 5′-(beta, gamma-dichloromethylene) triphosphate, by mammalian cells in vitro. J Bone Miner Res1213581367 Frith, JC, Mönkkönen, J, Blackburn, GM, Russel, RG, Rogers, MJ 1997Clodronate and liposome-encapsulated clodronate are metabolized to a toxic ATP analog, adenosine 5′-(beta, gamma-dichloromethylene) triphosphate, by mammalian cells in vitro. J Bone Miner Res1213581367
30.
Zurück zum Zitat Auriola, S, Frith, JC, Rogers, MJ, Koivuniemi, A, Mönkkönen, J 1997Identification of adenine nucleotide-containing metabolites of bisphosphonate drugs using ion-pair liquid chromatography-electrospray mass spectrometry.J Chromatogr B704187195CrossRef Auriola, S, Frith, JC, Rogers, MJ, Koivuniemi, A, Mönkkönen, J 1997Identification of adenine nucleotide-containing metabolites of bisphosphonate drugs using ion-pair liquid chromatography-electrospray mass spectrometry.J Chromatogr B704187195CrossRef
31.
Zurück zum Zitat Halasy-Nagy, JM, Rodan, GA, Reszka, AA 2001Inhibition of bone resorption by alendronate and risedronate does not require osteoclast apoptosis.Bone29553559CrossRefPubMed Halasy-Nagy, JM, Rodan, GA, Reszka, AA 2001Inhibition of bone resorption by alendronate and risedronate does not require osteoclast apoptosis.Bone29553559CrossRefPubMed
32.
Zurück zum Zitat Suri, S, Mönkkönen, J, Taskinen, M, Pesonen, J, Blank, MA, Phipps, RJ, Rogers, MJ 2001Nitrogen-containing bisphosphonates induce apoptosis of Cao-2 cells in vitro by inhibiting the mevalonate pathway: a model of bisphosphonate-induced gastrointestinal toxicity.Bone29336343CrossRefPubMed Suri, S, Mönkkönen, J, Taskinen, M, Pesonen, J, Blank, MA, Phipps, RJ, Rogers, MJ 2001Nitrogen-containing bisphosphonates induce apoptosis of Cao-2 cells in vitro by inhibiting the mevalonate pathway: a model of bisphosphonate-induced gastrointestinal toxicity.Bone29336343CrossRefPubMed
33.
Zurück zum Zitat Reszka, AA, Halasy-Nagy, J, Rodan, GA 2001Nitrogen-bisphosphonate block retinoblastoma phosphorylation and cell growth by inhibiting the cholesterol biosynthetic pathway in keratinocyte model for esophageal irritation.Mol Pharmacol59193202PubMed Reszka, AA, Halasy-Nagy, J, Rodan, GA 2001Nitrogen-bisphosphonate block retinoblastoma phosphorylation and cell growth by inhibiting the cholesterol biosynthetic pathway in keratinocyte model for esophageal irritation.Mol Pharmacol59193202PubMed
34.
Zurück zum Zitat Ayada, K, Oguri, S, Yamaguchi, K, Kumagai, K, Endo, Y 2003Elevation of histidine decarboxylase activity in the stomach of mice by ulcerogenic drugs.Eur J Pharmacol4606369CrossRefPubMed Ayada, K, Oguri, S, Yamaguchi, K, Kumagai, K, Endo, Y 2003Elevation of histidine decarboxylase activity in the stomach of mice by ulcerogenic drugs.Eur J Pharmacol4606369CrossRefPubMed
Metadaten
Titel
Effects of Weekly Administrations of Alendronate+Clodronate on Young Mouse Tibia: Localized Action at the Proximal Growth Plate
verfasst von
Y. Monma
H. Funayama
H. Mayanagi
Y. Endo
Publikationsdatum
01.01.2004
Erschienen in
Calcified Tissue International / Ausgabe 1/2004
Print ISSN: 0171-967X
Elektronische ISSN: 1432-0827
DOI
https://doi.org/10.1007/s00223-002-2156-5

Weitere Artikel der Ausgabe 1/2004

Calcified Tissue International 1/2004 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Schadet Ärger den Gefäßen?

14.05.2024 Arteriosklerose Nachrichten

In einer Studie aus New York wirkte sich Ärger kurzfristig deutlich negativ auf die Endothelfunktion gesunder Probanden aus. Möglicherweise hat dies Einfluss auf die kardiovaskuläre Gesundheit.

Intervallfasten zur Regeneration des Herzmuskels?

14.05.2024 Herzinfarkt Nachrichten

Die Nahrungsaufnahme auf wenige Stunden am Tag zu beschränken, hat möglicherweise einen günstigen Einfluss auf die Prognose nach akutem ST-Hebungsinfarkt. Darauf deutet eine Studie an der Uniklinik in Halle an der Saale hin.

Klimaschutz beginnt bei der Wahl des Inhalators

14.05.2024 Klimawandel Podcast

Auch kleine Entscheidungen im Alltag einer Praxis können einen großen Beitrag zum Klimaschutz leisten. Die neue Leitlinie zur "klimabewussten Verordnung von Inhalativa" geht mit gutem Beispiel voran, denn der Wechsel vom klimaschädlichen Dosieraerosol zum Pulverinhalator spart viele Tonnen CO2. Leitlinienautor PD Dr. Guido Schmiemann erklärt, warum nicht nur die Umwelt, sondern auch Patientinnen und Patienten davon profitieren.

Zeitschrift für Allgemeinmedizin, DEGAM

Typ-2-Diabetes und Depression folgen oft aufeinander

14.05.2024 Typ-2-Diabetes Nachrichten

Menschen mit Typ-2-Diabetes sind überdurchschnittlich gefährdet, in den nächsten Jahren auch noch eine Depression zu entwickeln – und umgekehrt. Besonders ausgeprägt ist die Wechselbeziehung laut GKV-Daten bei jüngeren Erwachsenen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.